Veradermics (MANE) Net Income towards Common Stockholders (2025 - 2026)
Veradermics (MANE) reported Net Income towards Common Stockholders of -$30.0 million for Q1 2026, down 105.81% on a YoY basis from $516.7 million in Q1 2025, and down 105.81% quarter-over-quarter from -$14.6 million in Q1 2025.
Veradermics (MANE) Net Income towards Common Stockholders (2025 - 2026) Analysis & Trends
Veradermics has reported Net Income towards Common Stockholders for 2 years, with the latest figure at -$30.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 105.81% year-over-year to -$30.0 million; the trailing twelve-month figure through Mar 2026 stood at -$44.6 million (changed N/A YoY), and the FY2025 full-year result was -$83.4 million, down 205.36% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$30.0 million, down from -$14.6 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$14.6 million in Q1 2025, with the low at -$30.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Veradermics | 2.13 Bn | 2.13 Bn | - | -30.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.01 Mn |
| Mar 31, 2025 | -14.58 Mn |